Camp4 Therapeutics Corp (CAMP): R&D Expense
$38.20M
Year ended 2025-12-31
$38.69M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.20M | -1.6% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $38.82M | -4.4% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $40.62M | n/a | 2025-03-27, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $38.20M | -1.6% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $11.80M | -12.4% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $3.07M | -6.8% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $280.9K | -1.1% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $58.03M | +28.7% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $18.12M | -23.6% |
Compare CAMP, MRKR, CRVO, XBIO side by side · Screen every company in Pharmaceutical Preparations ↗